Partial Dopamine Agonists and the Treatment of Psychosis

Title: Partial Dopamine Agonists and the Treatment of Psychosis

Volume: 3 Issue: 1

Author(s): Carol A. Tamminga

Affiliation:

Keywords: affinity, intrinsic activity, apomorphine, n-propyl-noraporphine, 3ppp aripiprazole

Abstract: Pharmacologic approaches that diminish dopamine-mediated neural transmission in brain have antipsychotic actions in humans. Blockade of D2 family dopamine receptors is the most common strategy. A paradoxical strategy of using dopamine agonists in particular circumstances to similarly diminish dopaminergic transmission is based on the known function of dopamine autoreceptors and on consideration of the intrinsic activity of dopamine agonists. It was apomorphine that first suggested the effectiveness of dopamine agonist treatment for schizophrenia. Now a partial dopamine agonist aripiprazole has come to market for psychosis and others are in development. This chapter reviews the clinical pharmacology of partial dopamine agonists and their development for the treatment of schizophrenia.

Cite this article as:

Tamminga A. Carol, Partial Dopamine Agonists and the Treatment of Psychosis, Current Neuropharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570159052773404